In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Noninvasive Prenatal Diagnostics: How Much Closer to Reality?

Executive Summary

Whether the astonishing missteps by Sequenom, which earlier this year disclosed it could not support its data for a non-invasive Down Syndrome test, were merely poor management or a reality check for the field of non-invasive prenatal disgnostics, the NIPD opportunity is compelling. But the profession also understandably balks at obtaining information that is not then clinically actionable -- an issue that could further amplify in importance as technologies like microarrays and direct DNA sequencing increase become more prevalent.
Advertisement

Related Content

J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General
Personalized Medicine In 2010: Welcome To The Establishment
Good Start Genetics Raises $18 Million For Sequencing-Based Testing
The How And When Of Applying Sequencing To Clinical Diagnostics
Dealmaking in 2009: A Look Back and A Glance Ahead
Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk
Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests
Illumina Goes Consumer
Sequenom's Failure Highlights an Underappreciated Risk of Biotech Investing
Sequenom Is Improving Prenatal Screening, in Steps

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel